Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TK1 | P04183 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28106173 | 0.84 | MMP1 (0.50) | KMT2ACACNA1BLMNAMEN1NPC1 | |
| SCHEMBL28190163 | 0.81 | LMNA (0.51) | CYP19A1KMT2ALMNACYP3A4MEN1 | |
| SCHEMBL17445703 | 0.81 | KMT2A (0.39) | KMT2ATK1CACNA1BLMNACYP1A2 | |
| SCHEMBL15457003 | 0.79 | CYP19A1 (0.42) | CYP19A1KMT2AAPPCACNA1BLMNA | |
| SCHEMBL1753615 | 0.79 | ABCB1 (0.42) | KMT2ATK1APPCACNA1BLMNA | |
| SCHEMBL5050338 | 0.78 | CYP19A1 (0.41) | CYP19A1KMT2AAPPCACNA1BLMNA | |
| SCHEMBL5050210 | 0.78 | CYP4F2 (0.44) | CYP19A1KMT2AAPPCACNA1BLMNA | |
| SCHEMBL19462887 | 0.75 | APP (0.44) | CYP19A1KMT2AAPPCACNA1BLMNA | |
| SCHEMBL5050208 | 0.75 | APP (0.44) | CYP19A1KMT2AAPPCACNA1BLMNA | |
| SCHEMBL5050194 | 0.74 | KMT2A (0.33) | CYP19A1KMT2ACACNA1BLMNAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | NOVARTIS AG (CH) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | CD2, CD22, CD2BP2 | CYP19A1 4823/4885KMT2A 1035/4885TK1 1357/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | CYP19A1 2165/4885KMT2A 2556/4885TK1 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.